| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Mainstream news |
| Population | Men |
| Source | Al Jazeera |
| URL | aljazeera.com/news/2026/9/18/pentagon-resumes-paused-testosterone-policy-amid-medical-experts-concerns (opens in a new tab) |
Specific Claim Evaluated
Medical experts have called the screening policy unnecessary and noted that testosterone injections could increase the risk of infertility.
Primary Research Supporting or Contradicting the Claim
Guidelines restrict diagnosis to men with symptoms and confirmed low levels and recommend against testosterone therapy in men planning fertility in the near term (Bhasin et al., 2018).
Corrected Evidence-Based Interpretation
Accurate. Exogenous testosterone suppresses gonadotropins and spermatogenesis; routine screening of asymptomatic men is not supported by guideline recommendations.
Rationale for Grade
The article reports the policy and the expert concerns without endorsing either, and the stated fertility risk is consistent with the known effect of exogenous testosterone. It does not attribute unsupported benefits to screening. The coverage is factual and balanced.
References
- Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID
Supporting excerpt: "We recommend making a diagnosis of hypogonadism only in men with symptoms and signs"